While it is mucosal IgA that is most likely to contribute protection from respiratory infections, for ease and simplicity, vaccine-induced Ab production studies primarily focus on the capacity of circulating IgG to neutralize SARS-CoV-2 variants [7,8,9,10,11]. Here, CD79A is linked to respiratory tract infectious disorder.